Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of a Selective Estrogen Receptor Modulator (LY353381) vs. Tamoxifen vs. Placebo in Premenopausal Women With and Increased Risk for Breast Cancer

NCT00253539 is registered in ClinicalTrials.gov with The Cleveland Clinic as lead sponsor.

NCT NCT00253539
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00253539 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of a Selective Estrogen Receptor Modulator (LY353381) vs. Tamoxifen vs. Placebo in Premenopausal Women With and Increased Risk for Breast Cancer
Lead sponsor
The Cleveland Clinic
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2002
Completion date
April 30, 2005
Enrollment
3 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, hereditary breast/ovarian cancer (brca1, brca2)